Therapeutic companion software specialist Voluntis has closed a Series D financing co-led by Bpifrance and Innovation Capital, plus Vesalius Biocapital, Qualcomm and existing investors.
With a total of EUR20.75 million (USD29 million), this fund raising is one of the largest rounds of investment in the m-health sector this year.
Voluntis existing Series C investors, CapDecisif Management, CM-CIC Capital Innovation and Sham, also participated in the round.
Voluntis embeds connectivity in therapeutics and medical intelligence in software. Dedicated to managing chronic conditions, Voluntis' digital solutions aim to enable treatment personalisation, support care coordination, and improve real-life outcomes.
Voluntis is active in diabetes, anticoagulation and haemophilia.
Voluntis will use the new funds to accelerate the development of its diabetes management solution, advance new programmes in other chronic diseases and ramp up its US operations.
"This strong investor syndicate is recognition of our relentless work to design the next-generation therapeutic solutions that combine digital and medical expertise in order to help solve some key daily problems of patients and care providers. This round is pivotal to grow Voluntis. I would like to thank the existing investors for their continued support and welcome the new investors who have stepped up to help us meet the exciting challenges ahead," says Pierre Leurent, founder and CEO, Voluntis.
Mailys Ferrère, director in charge of large venture investments at Bpifrance, says: "We are particularly pleased to make this significant investment in Voluntis, which is very well positioned to become a global leader in the m-health promising field. Voluntis fits perfectly into our investment strategy which focuses on groundbreaking technology companies in digital, life-sciences or cleantech."
Dr Florian Reinaud, partner at Innovation Capital, says: "We are delighted to co-lead this round of investment in Voluntis as the first investment from our new Innovative Healthcare Services fund. We share Voluntis' vision that combining best in class information technologies with therapeutics will contribute to solving some of the key issues faced by healthcare systems, notably those related to the management of chronic diseases and ageing. Such innovative solutions will likely become the backbone of an outcome-driven process that integrates care delivery and aligns the interests of patient, providers and payers across the continuum of care."
For this round of capital raising, Voluntis was advised by Silver Ocean Ventures' managing partner, Dr John Tchelingerian.
